Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of SPI-1005 for Prevention of Temporary Auditory Threshold Shift
NCT01444846Phase 2Completed
- Sponsor
- Sound Pharmaceuticals
- Start
- Sep 2011
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of ebselen in temporary auditory threshold shift (TTS) (4 arms), sponsored by Sound Pharmaceuticals. Primary endpoint: Change in Temporary Threshold Shift at 4 kHz. Started Sep 2011; status: completed.
02
Drugs
ebselen
03
Conditions
temporary auditory threshold shift (TTS)
Beyond the preview
Go deeper on NCT01444846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01444846.